Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Krishna Mohan Vadrevu|The Lancet Infectious Diseases|2021Cited by 364
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddhartha Dutta, Sanjay Rai et al.|The Lancet|2021Cited by 361
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trialRaches Ella, Siddarth Reddy, William C. Blackwelder et al.|medRxiv|2021Cited by 80
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up reportRaches Ella, Krishna Mohan Vadrevu|medRxiv|2020Cited by 38